
Alpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in Mild TBI Model
Alpha Cognition Reports Promising Preclinical Results for ALPHA-1062 in Military-Related Mild TBI Model Alpha Cognition Inc., a biopharmaceutical company focused on developing innovative treatments for neurodegenerative disorders, has announced encouraging preclinical data supporting the continued development of ALPHA-1062 for the…












